Total Payments
$52,256
2024 Payments
$162.59
Companies
8
Transactions
66
Medicare Patients
1,264
Medicare Billing
$181,567
Payment Breakdown by Category
Consulting$28,598 (54.7%)
Other$9,740 (18.6%)
Research$7,186 (13.8%)
Travel$4,802 (9.2%)
Food & Beverage$1,930 (3.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $28,598 | 12 | 54.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9,740 | 3 | 18.6% |
| Unspecified | $7,186 | 1 | 13.8% |
| Travel and Lodging | $4,802 | 17 | 9.2% |
| Food and Beverage | $1,930 | 33 | 3.7% |
Payments by Type
General
$45,070
65 transactions
Research
$7,186
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $30,077 | 29 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $8,457 | 21 | $0 (2023) |
| PFIZER INC. | $7,837 | 6 | $0 (2023) |
| Amgen Inc. | $3,105 | 2 | $0 (2022) |
| ARRAY BIOPHARMA INC | $2,636 | 5 | $0 (2024) |
| Iovance Biotherapeutics, Inc. | $89.03 | 1 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $29.91 | 1 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $24.90 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $162.59 | 4 | Iovance Biotherapeutics, Inc. ($89.03) |
| 2023 | $10,486 | 10 | PFIZER INC. ($7,837) |
| 2022 | $5,061 | 3 | Amgen Inc. ($3,000) |
| 2021 | $3,652 | 4 | Novartis Pharmaceuticals Corporation ($2,239) |
| 2020 | $10,314 | 12 | Novartis Pharmaceuticals Corporation ($10,289) |
| 2019 | $11,430 | 18 | Novartis Pharmaceuticals Corporation ($8,230) |
| 2018 | $3,965 | 14 | E.R. Squibb & Sons, L.L.C. ($3,788) |
| 2017 | $7,186 | 1 | NOVARTIS PHARMACEUTICALS CORPORATION ($7,186) |
All Payment Transactions
66 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/08/2024 | Iovance Biotherapeutics, Inc. | Amtagvi (Drug) | Food and Beverage | Cash or cash equivalent | $89.03 | General |
| Category: Oncology | ||||||
| 06/12/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI | Food and Beverage | In-kind items and services | $20.21 | General |
| Category: ONCOLOGY | ||||||
| 06/02/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $29.91 | General |
| Category: ONCOLOGY | ||||||
| 05/22/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI | Food and Beverage | In-kind items and services | $23.44 | General |
| Category: ONCOLOGY | ||||||
| 11/23/2023 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,520.00 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2023 | PFIZER INC. | LORBRENA (Drug) | Travel and Lodging | Cash or cash equivalent | $153.58 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2023 | PFIZER INC. | LORBRENA (Drug) | Travel and Lodging | Cash or cash equivalent | $38.40 | General |
| Category: ONCOLOGY | ||||||
| 11/03/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $56.67 | General |
| Category: Oncology | ||||||
| 10/23/2023 | ARRAY BIOPHARMA INC | MEKTOVI (Drug), BRAFTOVI | Food and Beverage | In-kind items and services | $55.58 | General |
| Category: ONCOLOGY | ||||||
| 10/20/2023 | PFIZER INC. | LORBRENA (Drug) | Consulting Fee | Cash or cash equivalent | $6,100.00 | General |
| Category: ONCOLOGY | ||||||
| 10/06/2023 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $1,189.16 | General |
| 10/06/2023 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $208.50 | General |
| 10/06/2023 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $147.43 | General |
| 05/23/2023 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI | Food and Beverage | In-kind items and services | $16.30 | General |
| Category: ONCOLOGY | ||||||
| 08/17/2022 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug) | Consulting Fee | Cash or cash equivalent | $2,025.00 | General |
| Category: ONCOLOGY | ||||||
| 06/05/2022 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug) | Food and Beverage | In-kind items and services | $36.29 | General |
| Category: ONCOLOGY | ||||||
| 03/11/2022 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| 10/21/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Consulting Fee | Cash or cash equivalent | $1,412.50 | General |
| Category: Oncology | ||||||
| 08/07/2021 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $122.58 | General |
| 06/23/2021 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug), TAFINLAR | Consulting Fee | Cash or cash equivalent | $2,030.00 | General |
| Category: ONCOLOGY | ||||||
| 03/10/2021 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $86.57 | General |
| 07/17/2020 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug), TAFINLAR | Consulting Fee | Cash or cash equivalent | $3,480.00 | General |
| Category: ONCOLOGY | ||||||
| 06/22/2020 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $1,740.00 | General |
| 02/26/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $24.90 | General |
| Category: ONCOLOGY | ||||||
| 02/18/2020 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,740.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $7,186 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 289 | 446 | $170,528 | $41,207 |
| 2022 | 10 | 333 | 543 | $188,541 | $48,929 |
| 2021 | 8 | 328 | 553 | $177,404 | $50,851 |
| 2020 | 8 | 314 | 547 | $170,808 | $40,580 |
Total Patients
1,264
Total Services
2,089
Medicare Billing
$181,567
Procedure Codes
33
All Medicare Procedures & Services
33 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 82 | 150 | $80,321 | $16,767 | 20.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 124 | 174 | $45,968 | $12,616 | 27.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 20 | 55 | $15,745 | $5,127 | 32.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 26 | 26 | $15,903 | $3,657 | 23.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 11 | 11 | $6,689 | $1,488 | 22.2% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 11 | 11 | $3,612 | $1,018 | 28.2% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Facility | 2023 | 15 | 19 | $2,290 | $534.09 | 23.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 80 | 158 | $80,988 | $18,310 | 22.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 131 | 207 | $52,782 | $15,182 | 28.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 25 | 72 | $20,376 | $6,029 | 29.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 26 | 26 | $14,138 | $3,689 | 26.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 12 | 12 | $6,931 | $1,939 | 28.0% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 13 | 13 | $3,962 | $1,113 | 28.1% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 11 | 12 | $3,034 | $887.97 | 29.3% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2022 | 11 | 17 | $2,768 | $823.32 | 29.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 11 | 11 | $1,782 | $519.31 | 29.1% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Facility | 2022 | 13 | 15 | $1,780 | $436.49 | 24.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 134 | 231 | $56,676 | $17,701 | 31.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 63 | 103 | $50,763 | $12,095 | 23.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 31 | 105 | $29,715 | $8,892 | 29.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 29 | 29 | $15,650 | $4,433 | 28.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 19 | 19 | $10,146 | $3,120 | 30.7% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 18 | 19 | $5,505 | $1,659 | 30.1% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 12 | 18 | $4,383 | $1,487 | 33.9% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2021 | 22 | 29 | $4,566 | $1,465 | 32.1% |
About Dr. Isabella Glitza, M.D
Dr. Isabella Glitza, M.D is a Internal Medicine healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/19/2007. The National Provider Identifier (NPI) number assigned to this provider is 1215137187.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Isabella Glitza, M.D has received a total of $52,256 in payments from pharmaceutical and medical device companies, with $162.59 received in 2024. These payments were reported across 66 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($28,598).
As a Medicare-enrolled provider, Glitza has provided services to 1,264 Medicare beneficiaries, totaling 2,089 services with total Medicare billing of $181,567. Data is available for 4 years (2020–2023), covering 33 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Internal Medicine, Student in an Organized Health Care Education/Training Program
- Location Houston, TX
- Active Since 07/19/2007
- Last Updated 10/28/2014
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1215137187
Products in Payments
- MEKINIST (Drug) $15,373
- OPDIVO (Biological) $8,457
- TAFINLAR (Drug) $7,365
- LORBRENA (Drug) $6,292
- BRAFTOVI (Drug) $2,580
- IMLYGIC (Biological) $105.09
- Amtagvi (Drug) $89.03
- MEKTOVI (Drug) $55.58
- LIBTAYO (Biological) $29.91
- KEYTRUDA (Biological) $24.90
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Houston
Stephen Pappas, M.d, M.D
Internal Medicine — Payments: $1.6M
Internal Medicine $1.6M
Mohamed Othman, Md, MD
Internal Medicine — Payments: $1.1M
Internal Medicine $1.1M
Dr. Aung Naing, Md, MD
Internal Medicine — Payments: $925,146
Internal Medicine $925,146
Miguel Escobar, M.d, M.D
Internal Medicine — Payments: $924,228
Internal Medicine $924,228
Dr. Christie Ballantyne, Md, MD
Internal Medicine — Payments: $815,154
Internal Medicine $815,154
John Heymach, M.d, M.D
Internal Medicine — Payments: $786,947
Internal Medicine $786,947